{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:56:46Z","timestamp":1773878206949,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chong Kun Dang Pharmaceutical Corp."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The present study aimed to compare the efficacy and safety of intravesical gemcitabine versus Bacillus Calmette\u2013Gu\u00e9rin administered after transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer. Methods: A comprehensive literature search was conducted using PubMed, Embase, and the Cochrane Library databases up to September 2025. Studies were eligible for inclusion if they were comparative studies evaluating intravesical gemcitabine versus Bacillus Calmette\u2013Gu\u00e9rin following transurethral resection of bladder tumor. The primary outcomes were recurrence-free survival, progression-free survival, and incidence of adverse events. Pooled hazard ratios were calculated using a random-effects model based on log hazard ratios and standard error values. Results: Seven studies comprising approximately 774 patients were included in this analysis. The pooled hazard ratio was 0.80 (95% confidence interval, 0.42\u20131.53) for recurrence-free survival and 0.76 (95% confidence interval, 0.46\u20131.26) for progression-free survival, indicating no significant difference between gemcitabine and Bacillus Calmette\u2013Gu\u00e9rin. However, gemcitabine was associated with a significantly lower incidence of adverse events, with a pooled odds ratio of approximately 0.48 (95% confidence interval, 0.27\u20130.86). Risk-of-bias assessment revealed that most randomized trials had \u201csome concerns\u201d based on the Risk of Bias 2 tool, whereas non-randomized studies were rated as having \u201cmoderate to serious\u201d risk of bias according to the Risk of Bias in Non-randomized Studies of Interventions tool. Conclusions: Gemcitabine demonstrated an oncologic efficacy comparable to that of Bacillus Calmette\u2013Gu\u00e9rin in terms of recurrence and progression outcomes while showing a substantially lower incidence of treatment-related toxicities.<\/jats:p>","DOI":"10.3390\/cancers18060990","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:12:26Z","timestamp":1773853946000},"page":"990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette\u2013Gu\u00e9rin for Bladder Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Do Kyung","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-1310","authenticated-orcid":false,"given":"Jinhyung","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Urology, Yongin Severance Hospital, College of Medicine, Yonsei University, Yongin 16995, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Kyou","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-756X","authenticated-orcid":false,"given":"Sungun","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-8393","authenticated-orcid":false,"given":"Kwang Suk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7303-6256","authenticated-orcid":false,"given":"Kyo Chul","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-8833","authenticated-orcid":false,"given":"Kang Su","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea"},{"name":"Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the united states, europe and asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3349\/ymj.1993.34.4.356","article-title":"Production of tumor necrosis factor by intravesical administration of bacillus calmette gu\u00e9rin in patients with superficial bladder cancer","volume":"34","author":"Kim","year":"1993","journal-title":"Yonsei Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3349\/ymj.2016.57.4.855","article-title":"Prognostic factors for recurrence and progression in korean non-muscle-invasive bladder cancer patients: A retrospective, multi-institutional study","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille calmette-gu\u00e9rin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Prasanna, T., Craft, P., Balasingam, G., Haxhimolla, H., and Pranavan, G. (2017). Intravesical gemcitabine versus intravesical bacillus calmette-gu\u00e9rin for the treatment of non-muscle invasive bladder cancer: An evaluation of efficacy and toxicity. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00260"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase i trial of intravesical gemcitabine in bacillus calmette-gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.21037\/tcr-21-291","article-title":"Efficacy and toxicity in scheduled intravesical gemcitabine versus bacille calmette-gu\u00e9rin for ta and t1 bladder cancer: A systematic review and meta-analysis","volume":"10","author":"Lu","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.2147\/OTT.S170477","article-title":"The efficacy and safety of intravesical gemcitabine vs bacille calmette-gu\u00e9rin for adjuvant treatment of non-muscle invasive bladder cancer: A meta-analysis","volume":"11","author":"Ye","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4111\/icu.20230313","article-title":"Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus calmette-gu\u00e9rin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study","volume":"65","author":"Choi","year":"2024","journal-title":"Investig. Clin. Urol."},{"key":"ref_11","first-page":"123","article-title":"Intravesical gemcitabine versus intravesical bacillus calmette-guerin for the treatment of intermediate-risk non-muscle invasive bladder cancer: A randomized controlled trial","volume":"20","author":"Djafari","year":"2023","journal-title":"Urol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/JU.0000000000004472","article-title":"Gemcitabine vs. bacillus calmette-gu\u00e9rin for intravesical therapy in treatment-na\u00efve low-grade intermediate-risk nonmuscle-invasive bladder cancer","volume":"213","author":"Khene","year":"2025","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-i: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Grade working group. Grade: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: An update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp. Clin. Trials"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nemati, M., Hsu, C.Y., Nathiya, D., Kumar, M.R., Oghenemaro, E.F., Kariem, M., Kaur, P., Bhanot, D., Hjazi, A., and Azam Saedi, T. (2025). Gemcitabine: Immunomodulatory or immunosuppressive role in the tumor microenvironment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1536428"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille calmette-gu\u00e9rin after initial bacille calmette-gu\u00e9rin failure in non-muscle-invasive bladder cancer: A multicenter prospective randomized trial","volume":"116","author":"Damiano","year":"2010","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose bacillus calmette-gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase ii trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus calmette-gu\u00e9rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: A randomised prospective study","volume":"84","author":"Porena","year":"2010","journal-title":"Urol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.urology.2009.05.094","article-title":"Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer","volume":"74","author":"Maffezzini","year":"2009","journal-title":"Urology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","article-title":"Intravesical gemcitabine: A phase 1 and pharmacokinetic study","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, R., Li, Y., Song, J., Gao, K., Chen, K., Yang, X., Ding, Y., Ma, X., Wang, Y., and Li, W. (2020). Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized controlled trial. BMC Urol., 20.","DOI":"10.1186\/s12894-020-00610-9"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.3934\/mbe.2019267","article-title":"Bcg and il\u20142 model for bladder cancer treatment with fast and slow dynamics based on spvf method-stability analysis","volume":"16","author":"Nave","year":"2019","journal-title":"Math. Biosci. Eng."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yosef, M., Bunimovich-Mendrazitsky, S., and Nave, O. (2025). Multiscale dynamics of mmc chemotherapy in bladder cancer: The spvf approach. Mathematics, 13.","DOI":"10.3390\/math13243974"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euf.2018.07.005","article-title":"Combination intravesical chemotherapy for non-muscle-invasive bladder cancer","volume":"4","author":"Steinberg","year":"2018","journal-title":"Eur. Urol. Focus"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:17:52Z","timestamp":1773854272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060990"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060990","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}